Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sperm-tail PG-rich repeat containing protein 4 (STPG4), previously known as C2orf61, is a protein predicted to be involved in chromatin binding and histone binding, with a specialized role in the epigenetic reprogramming of the paternal genome after fertilization. It specifically contributes to the conversion of 5-methylcytosine to 5-hydroxymethylcytosine in zygotes, influencing DNA demethylation dynamics in the male pronucleus[2][13][4]. STPG4 is also implicated in protein localization within sperm tail structures and may play a role in the regulation of sperm motility and fertility, though direct functional and disease links in humans are not fully described[1][5]. STPG4 is not currently recognized as a therapeutic target, there are no known interacting drugs, and it is not established as a diagnostic or predictive biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sperm-tail PG-rich repeat containing protein 4 (STPG4).